ombitasvir, paritaprevir and ritonavir was approved for use in combination with ribavirin for treatment of genotype 4 hepatitis C infections. It is the first treatment option for genotype 4 infections that does not require interferon. It can achieve 100% cure rates. That same year, daclatasvir (Daklinza) was approved to treat genotype 3 infections. This is given with sofosbuvir (Sovaldi) with cure rates up to 98%.